Guidelines of the Spanish society of cardiology on cardiomyopathy and myocarditis;Guias de practica clinica de la sociedad espanola de cardiologia en miocardiopatias y miocarditis

Revista Espanola de Cardiologia

Volumn 53, Issue 3, 2000, Pages 360-393

  Basilio, Galve ^b   Manterola, Fernando Alfonso ^b   Rodés, Manuel Ballester ^b   Beiras, Alfonso Castro ^b   De Soria Pantoja, Rafael Fernández ^b   Lado, Manuel Penas ^b   Domí'nguez, José Sánchez ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b NONE

Author keywords

Cardiomyopathy; Clinical guidelines; Myocarditis

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; INOTROPIC AGENT;

CARDIOMYOPATHY; CATHETER ABLATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ELECTROSTIMULATION THERAPY; HISTOPATHOLOGY; HUMAN; MEDICAL SOCIETY; MYOCARDITIS; PATHOGENESIS; PRACTICE GUIDELINE; REVIEW; SPAIN; DIFFERENTIAL DIAGNOSIS; PATHOLOGY;

CARDIOMYOPATHIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MYOCARDITIS; SPAIN;

EID: 0034091081     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(00)75104-9     Document Type: Review

References (200)

1. Richardson P, McKenna WJ, Bristow M, Maisch B, Mautner B, O'Connell J et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of the Cardiomyopathies. Circulation 1996; 93: 841-842.
2. Abelmann WH. Classification and natural history of primary myocardial disease. Prog Cardiovasc Dis 1984; 27: 73-94.
3. Abelmann WH, Lorell BH. The challenge of cardiomyopathy. J Am Coll Cardiol 1989; 13: 1219-1239.
4. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandemburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-531.
5. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331: 1564-1575.
6. Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels VV et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung and Blood Institute Workshop). Am J Cardiol 1992; 69: 1458-1466.
7. Urbano-Márquez A, Estruch R, Navarro-López F, Grau JM, Mont LI, Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989; 320: 409-415.
8. Kasper EK, Agema WR, Hutchins GM, Deckers JW, Hare JM, Baugham KL. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 patients. J Am Coll Cardiol 1994; 23: 586-590.
9. Ferrans VJ. Pathologic anatomy of the dilated cardiomyopathies. Am J Cardiol 1989; 64: 9C-11C.
10. Nogami K, Kusachi S, Nunoyama H, Kondo J, Endo C, Yamamoto K et al. Extracellular matrix components in dilated cardiomyopathy. Immunohistochemical study of endomyocardial biopsy specimens. Jpn Heart J 1996; 37: 483-494.
11. Kuhl U, Noutsias M, Seeberg B, Schultheiss H-P. Immunohistological evidence for chronic intramyocardial inflamatory process in dilated cardiomyopathy. Heart 1996; 75: 295-300.
12. Mestroni L, Rocco C, Gregori D, Sinagra G. Di Lenarda A. Miocic S et al. Familial dilated cardiomyopathy: Heart Muscle Disease Study Group. J Am Coll Cardiol 1999; 34: 181-190.
13. Neumann DA. Autoimmunity in idiopathic dilated cardiomyopathy. Mayo Clin Proc 1994; 69: 193-195.
14. Mestroni L, Krajinovic M, Severini GM, Pinamonti B, Di Lenarda A, Giacca M et al. Familial dilated cardiomyopathy. Br Heart J 1994; 72 (Supl): 35-41.
15. Michels VV, Driscol DJ, Miller FA. Familial aggregation of idiopathic dilated cardiomyopathy. Am J Cardiol 1985; 55: 1232-1233.
16. Mestroni L, Miani D, Di Lenarda A, Silvestri F, Bussani R, Filippi G et al. Clinical and pathologic study of familial dilated cardiomyopathy. Am J Cardiol 1990; 65: 1449-1453.
17. Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll DJ et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Fingl J Med 1992; 326: 77-82.
18. Keeling PJ, Gang G, Smith G, Seo H, Bent SE, Murday V et al. Familial dilated cardiomyopathy in the United Kingdom. Br Heart J 1995; 73: 417-421.
19. Baig MK, Goldman JH, Caforio ALP, Coonar AS, Keeling PJ, McKenna WJ. Familial dilated cardiomyopahy: cardiac abnormalities are common in asymptomatic relatives and may represent early cisease. J Am Coll Cardiol 1998; 31: 195-201.
20. Grunig E, Tasman JA, Kuherer H, Franz W, Kubler W, Katus HA. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol 1998; 31: 186-194.
21. Mestroni L, Maisch B, McKenna WJ, Schwartz K, Charron P, Rocco C et al. Guidelines for the study of familial dilated cardiomyopathies. Eur Heart J 1999; 20: 93-102.
22. Olson TM, Michels VV, Thibodeau SN, Tai Y-S, Keating MT. Actin mutations in dilated cardiomyopahy, a heritable form of heart failure. Science 1998; 280: 750-752.
23. Olson TM, Thibodeau SN, Lundquist PA et al. Exclusion of a primary gene defect at the HLA locus in familial dilated cardiomyopathy. J Med Genet 1995; 32: 876-880.
24. Anguita M, Torres F, Vallés F. Marcadores de la actuación clínica en pacientes con miocardiopatía dilatada. Rev Esp Cardiol 1996; 49: 682-692.
25. Cruz FE, Cheriex EC, Smeets JL, Atié J, Peres AK, Penn OCKM et al. Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia. J Am Coll Cardiol 1990; 16: 739-744.
26. Pinamonti B, Di Lenarda A, Sinagra G, Camerini F. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. Heart Muscle Disease Study Group. J Am Coll Cardiol 1993; 22: 808-815.
27. Glamann DB. Lange RA, Corbett JR, Hillis LD. Utility of various radionuclide techniques for distinguishing ischemic from non-ischemic dilated cardiomyopathy. Arch Intern Med 1992; 152: 769-772.
28. Sharp SM, Sawada SG, Segar DS, Ryan T, Kovacs R, Fineberg NS et al. Dobutamine stress echocardiography: Detection of coronary artery disease in patients with dilated cardiomyopathy. J Am Coll Cardiol 1994; 24: 934-939.
29. Crespo MO, Escaned J. Valoración funcional del paciente en insuficiencia cardíaca. Indicadores pronósticos. Monocardio 1995; 39: 65-75.
30. Mancici DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson J. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83: 778-786.
31. Leonen MF, O'Connell JB. End-stage heart failure and timing of heart transplantation. En: Camerini F, Gavazzi A, De María, editores. Advances in cardiomyopathies. Milan: Spinger-Verlag Italia, 1998, 280-293.
32. ACC/AHA Task Force Report. Guidelines for the Evaluation and Management of Heart Failure. J Am Coll Cardiol 1995; 26: 1376-1398.
33. Stevenson LW. Selection and management of patients for cardiac transplantation. Curr Opin Cardiol 1994; 9: 315-325.
34. Starling RC, Van Fossen DB, Hammer DF, Unverferth DV. Morbidity of endomyocardal biopsy in cardiomyopathy. Am J Cardiol 1991; 68: 133-136.
35. Mason JW. Endomyocardial biopsy and the causes of dilated cardiomyopathy. J Am Coll Cardiol 1994; 23: 591-592.
36. Figulla HR, Stillesiegener M, Mall G, Heim A, Kreuzer H. Myocardial enterovirus infection with left ventricular dysfunc-tion: a benign disease compared with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1995; 25: 1170-1175.
37. Borggrefe M, Block M, Breithardt G. Prevention of sudden death in patients with dilated cardiomyopathy. En: Camerini F, Gavazzi A, De María, editores. Advances in cardiomyopathies. Milan: Spinger-Verlag Italia, 1998; 220-228.
38. De Maria R, Gavazzi A, Caroli A, Ometto R, Biagini A, Camerini F et al. Ventricular arrhythmias in dilated cardiomyopathy as an independent prognostic hallmark. Italian Multicenter Cardiomyopathy Study (SPIC) Group. Am J Cardiol 1992; 69: 1451-1457.
39. Mancini DM, Wong KL, Simson MB. Prognostic value of an abnormal signal-averaged electrocardiogram in patients with non-ischemic congestive cardiomyopathy. Circulation 1993; 87: 1083-1092.
40. Pinsky DJ, Sciacca RR, Steinberg JS. QT dispersion as a marker of risk in patients awaiting heart transplantation. J Am Coll Cardiol 1997; 29: 1576-1584.
41. Ponikowski P, Anker SD, Chua TP, Szelemej R. Piepoli M, Adamopoulos S et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemie or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 79: 1645-1650.
42. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME et al. A clinical trial of immunosupresive therapy for myocarditis. N Engl J Med 1995; 333: 269-275.
43. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-115.
44. Keren A, Gottlieb S, Tzivoni D, Stern S, Yarom R, Billingham ME et al. Mildly dilated congestive cardiomyopathy. Use of prospective diagnostic criteria and description of the clinical course without heart trasplanlation. Circulation 1990; 81: 506-517.
45. Bart BA, Shaw LK, McCants CB, Fortin DF, Lee KL, Califf RM et al. Clinical determinants of mortality in patients with angiographically disgnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997; 30: 1002-1008.
46. Uretsky BF. Diagnostic considerations in the adult patient with cardiomyopathy or congestive heart failure. Cardiovasc Clin 1988; 19: 35-56.
47. Freire Castroseiros E, Penas Lado M, Castro Beiras A. Cocaína y corazón. Rev Esp Cardiol 1998; 51: 396-401.
48. Packer M, Cohn JN, Consensus Recommendations for the Management of Chronic Heart Failure. Am J Cardiol 1999; 83: 2A-38A.
49. Dargie HJ, McMurray JJ. Diagnosis and management of heart failure. Br Med J 1994; 308: 321-328.
50. Cohn JN, Drug therapy: the management of chronic heart failure. N Engl J Med 1996; 335: 490-498.
51. Follath FF, Cleland JG, Klein W, Murphy R. Etiology and response to drug treatment in heart failure. J Am Coll Cardiol 1998; 32: 1167-1172.
52. Cohn JN. Medical treatment of heart failure: Problems in dilated cardiomyopathy. En: Camerini F, Gavazzi A, De María, editores. Advances in cardiomyopathies. Milan: Spinger-Verlag Italia, 1998; 229-235.
53. Navarro-López F, de Teresa E, López Sendón JL, Castro Beiras A. Guías del diagnóstico, clasificación y tratamiento de la insuficiencia cardíaca y del shock cardiogénico. Grupo de Trabajo de Insuficiencia Cardíaca de la Sociedad Española de Cardiología. Rev Esp Cardiol 1999; 52 (Supl 2): 1-54.
54. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
55. Cohn JN, Johnson G, Ziesche S. Cobb F, Francis G, Tristani F et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
56. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
57. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trialsof angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-1456.
58. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
59. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol 1996; 28: 1323-1327.
60. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA et al, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-1446.
61. White M, Rouleau J-L, Pericak D, Young J, McKelvie R, Held P et al, on behalf of the RESOLVD Study Group. Effects of metoprolol-CR in patients with ischaemic and dilated cardiomyopathy: the RESOLVD Pilot Study (phase II) [resumen]. Eur Heart J 1998; 19 (Supl): 308.
62. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
63. The International Steering Commiittee. Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol 1997; 80 (Supl 9B): 54J-58J.
64. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355.
65. Packer M, Colucci WS, Sackner-Berstein JD, Liang C, Goldscher DA, Freeman I et al, for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996; 94: 2793-2799.
66. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE et al, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function anf survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-2816.
67. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel J-P. Clinical effects of beta-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98: 1184-1191.
68. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
69. Pitt B, Segal R, Martínez FA, Meurers G, Cowley AJ, Thomas I et al, on behalf of ELITE Study Investigators. Randomised Trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
70. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN et al, for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine in morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-1114.
71. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman B, Loeb H et al, for the Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Effect of the calcium antagonist felodipine as suplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation 1997; 96; 856-863.
72. Figulla HR, Gietzen F, Zeymer U, Raiber M, Heggelmann J, Soballa R et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Circulation 1996; 94: 346-352.
73. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. Am J Cardiol 1996; 78: 902-907.
74. Pitt B. Presentación de resultados del Estudio RALES. American Heart Association Scientific Sessions. Dallas, Texas, noviembrede 1998.
75. Unverferth DV, Maorien RD, Lewis RP, Leier CV. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1980; 100: 622-630.
76. Liang CS, Sherman LG, Doherty JM, Wellington K, Lee VW, Hood WN Jr et al. Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation 1984; 69: 113-119.
77. Krell MJ, Kline EM, Bates ER, Hodgson JM, Dilworth LR, Lanfer N et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986; 112: 787-791.
78. Packer M. Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 1985; 72: 681-685.
79. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
80. Packer M. Hemodynamic consequences of antiarrhythmic drug therapy in patients with chronic heart failure. J Cardiovasc Electrophysiol 1991; 2 (Supl): S240-S247.
81. Pratt CM, Eaton T, Francis M, Woolbert S, Mahmariam J, Roberts R et al. The inverse relationship between baseline left vebtricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J 1989; 118: 433-440.
82. Doval HC, Hui DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe heart failure. Lancet 1994; 344: 493-498.
83. Massie BM, Fisher SG, Deedwania PC, Singh BN, Fletcher RD, Singh SN. Effects of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 1996; 93: 2128-2134.
84. Shivkumar K, Jafri SM, Gheorghiade M. Antithrombotic therapy in atrial fibrillation: a review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) trial. Progr Cardiovasc Dis 1996; 38: 337-342.
85. Mulder P, Richard V, Derumeaux G, Hogie M, Henry P, Lallemand F et al. Role of endogenous endothelin in chronic heart failure. Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics and cardiac remodeling. Circulation 1997; 96: 1976-1982.
86. Massie BM, Berk MR, Brozena SC, Ekayam U, Plehn JF, Kukin ML et al. Can further benefit be achieved by added flosequinan in patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the Flosequinan-ACE Inhibitor Trial (FACET). Circulation 1993; 88: 492-501.
87. Califf RM, Adams KF, McKenna WJ, Georgiade M, Uretsky BF, McNulty SE et al. A randomized controlled trial of epoprostenol trerapy for severe congestive heart failure: The Folan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44-54.
88. Kleber FX, Niemoller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure trial. Br Heart J 1992; 67: 289-296.
89. Gold MR, Feliciano Z, Gottlieb SS, Fisher ML. Dual chamber pacing with a short atrioventricular delay in congestive heart failure: a randomized study. J Am Coll Cardiol 1995; 26: 967-973.
90. Tascón JC, Kabbani Z, Albarrán A, Carnero A. Rodríguez J. Impacto de la estimulación cardíaca eléctrica sobre la función ventricular y la historia natural de los pacientes con miocardiopatía. Rev Esp Cardiol 1996; 49: 598-608.
91. Laks H, Marelli D. The current role of left ventricular reduction for treatment cf heart failure. J Am Coll Cardiol 1998; 32: 1809-1810.
92. Viganò M, Rinaldi M, Pagani F, Minzioni G, D'Armini AM, Ardemagni E. Left ventricular assist device as bridge to transplantation. En Camerini F, Gavazzi A. De María, editores. Advances in cardiomyopathies. Milan: Spinger-Verlag Italia, 1998; 303-312.
93. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-785.
94. Maron BJ, Bonow RO, Cannon III RO, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of cinical manifestations, pathophysiology and therapy. N Engl J Med 1987; 316: 844-852.
95. McKenna WJ. Alfonso F. Arrhythmias in the cardiomyopathies and mitral value prolapse. Progress in Cardiology 1/2. En: Zipes DP, Rowlands DJ, editores. Filadelfia: Lea & Febiger, 1988; 59-75.
96. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovase Dis 1985: 28: 1-83.
97. Maron BJ, Spirito P, Wesley Y. Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 1986; 315: 610-614.
98. McKenna WJ, Stewart JT, Nihoyannopoulos P. McGinty F, Davies MJ. Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass. Br Heart J 1990; 63: 287-290.
99. Maron BJ, McKenna WJ, Elliot P, Spirito P. Frenneaux MP, Keren A et al. Hypertrophie cardiomyopathy. JAMA 1999; 282:2302-2302.
100. Jarcho JA, MoKenna WJ, Pare JAP, Solomon SD, Holcombe RF, Dickie S et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14ql. N Engl J Med 1989; 321: 1372-1378.
101. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seiman CE et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophie cardiomyopathy. N Engl J Med 1992; 326: 1108-1111.
102. Niimura H, Bachinski LL, Sangwatoraj S, Watkins H, Chudley AE, McKenna W et al. Human cardiac myosin binding protein C mutations cause late-onset familial hypertrophie cardiomyopathy. N Engl J Med 1998; 338: 1248-1257.
103. McKenna WJ. Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophie cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 1997; 77: 130-132.
104. Maron BJ, Roberts WJ, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982; 65: 1388-1394.
105. McKenna WJ, Camm AJ. Sudden Death in Hypertrophie cardiomyopathy. Assessment of patients at high risk. Circulation 1989; 80: 1489-1492.
106. Spirito P, Maron BJ. Perspectives on the role of new treatment strategies in hypertrophie obstructive cardiomyopathy. J Am Coll Cardiol 1999:33: 1071-1075.
107. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophie cardiomyopath successfully resucitated after cardiac arrest. J Am Coll Cardiol 1989; 13: 2183-2187.
108. Alfonso F. Mnerte súbita en la miocardiopatía hipertrófica. Rev Esp Cardiol 1996; 49: 288-304.
109. Maron BJ, Klues HG. Surviving competitive athletics with hypertrophic cardiomyopathy. Am J Cardiol 1994; 73: 1098-1104.
110. Spirito P, Rapezzi C, Bellone P, Betocchi S, Autore C, Conte MR et al. Infective endocarditis in hypertrophic cardiomyopathy. Prevalence, incidence, and indications for antibiotic profilaxis. Circulation 1999; 99: 2132-2137.
111. Spirito LM, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engt J Med 1989; 320: 794-798.
112. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999: 281: 650-655.
113. McKenna WJ, Franklin RC, Nihoyanopoulos P, Robinson KC. Deanfield .IE. Arrythmias and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988; II: 147-151.
114. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patientes with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 22: 796-804.
115. Sadoul N, Prasad K, Elliott PM. Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997; 96: 2987-2991.
116. Thomson HL, Morris-Thurgood J. Atherton J, Frenneaux M. Reduced cardiopulmonary baroreflex sensitivity in patientes with hypertrophic cardiomyopathy. J Am Coll Cardiol 1998; 31 : 1377-1382
117. Sneddon JF, Slade A, Seo H, Camm AJ, McKenna WJ. Assessment of the diagnostic value of head-up tilt testing in the evaluation of syncope in hypertrophic cardiomyopathy. Am J Cardiol 1994; 73: 601-604.
118. Yetman AT, MacDonald C, McCrindle BW, Freedom RM, Gow RM. Myocardial bridging with coronary compression in children with hypertrophie cardiomyopathy: a risk factor for sudden death. N Engl J Med 1998; 339: 1201-1209.
119. Alfonso F. McKenna WJ. Milking in hypertrophic cardiomyopathy [carta]. J Am Coll Cardiol 1999; 34: 949-950.
120. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patientes with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981; 48: 252-257.
121. Monserrat L, Elliott P, Prasad K. Penas-Lado M, Castro Beiras A. McKenna WJ. Non-sustained ventricular tachycardia and sudden death in hypertrophic cardiomyopathy. J Am Coll Cardiol 1998; 31: Supl 26A.
122. Spirito P, Rapezzi C, Autore C, Bruzzi P, Bellone P, Ortolami P et al. Prognosis of asymptomatic patientes with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia Circulation 1994; 90: 2743-2747.
123. Cecchi F. Olivotto I, Montereggi A, Squillatini G, Dolara A. Maron BJ. Prognostic value of nonsustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 1998; 79: 331-336.
124. Elliot PM. Poloniecki J, Sharma S, Dickie S, McKenna WJ. Amiodarone and sudden death in patients with hypertrophic cardiomyopathy. Heart 1998; 79: 3.
125. Watson RM, Schwartz JL, Maron BJ, Tucker E, Rosing DR, Josephson ME. Inducible polymorphic ventricular tachycardia and ventricular fibrillation in a subgroup of patients with hypertrophic cardiomyopathy and high risk for sudden death. J Am Coll Cardiol 1987; 10:761-769.
126. Scanlon PJ, Faxon DP, Ritchie JL, Gibbons RJ, Audet AM, Carabello B et al. ACC/AHA Guidelines for coronary angiography. J Am Coll Cardiol 1999; 33: 1756-1824.
127. Robinson K. Frenncaux MP, Stockins B, Karatasakis G, Polonieki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990; 15: 1279-1285.
128. Alfonso F. Frenneaux MP, McKenna WJ. Clinical sustained uniform ventricular tachycardia in hypertrophic cardiomyo-pathy: association with left ventricular apical aneurysm. Br Heart J 1989; 61: 178-182.
129. Primo J, Geelen P, Brugada J, Filho AL, Mont LL, Wellens F et al. Hypertrophic cardiomyopathy: role of implantable cardioverter-defibrillator. J Am Coll Cardiol 1998; 31: 1081-1085.
130. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patientes with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33: 1596-1601.
131. Adelman AG, Shah PM, Gramiak R, Wigle ED. Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J 1970; 32: 804-811.
132. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Eng J Med 1982; 307: 997.
133. Pollick C. Disopyramide in hypertrophic cardiomyopathy II. Non-invasive assessment after oral administration. Am J Cardiol 1988; 62: 1252-1255.
134. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53: 412-417.
135. Fananapazir L, Leon MB, Bonow RO, Tracy CM, Canon III RO, Epstein SE. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991; 67: 169-174.
136. Furlan AJ, Cracium AR, Raju NR, Hart N. Cerebrovascular complications associated with idiopathic hyepertrophic subaortic stenosis. Stroke 1984; 15: 282-287.
137. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 1992; 339: 1318-1323.
138. Fananapazir L, Cannon III RO, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy. Circulation 1992; 85: 2149-2161.
139. Kappenberger L, Linde C, Daubert C, McKenna WJ, Meisel E, Sadoul N et al, and the PIC study group. Pacing in hypertrophic obstructive cardiomyopathy. Eur Heart J 1997; 18: 1249-1256.
140. Linde C, Gadler F, Kappenberger L, Ryden L, for the PIC study group. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. Am J Cardiol 1999; 83: 903-907.
141. Nishimura RA, Hayes DL, Ilstrup D, Holmes DR, Tajik AJ. Effect of dual chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler echocardiographic and cardiac catheterization hemodynamic study. J Am Coll Cardiol 1996; 27: 421-430.
142. Nishimura RA, Trusty JM, Hayes DL. Ilstrup DM, Larson DR, Hayes SN et al. Dual-chamber pacing for hypertrophic cardiomyoapthy: a randomized, double blind, cross-over trial. J Am Coll Cardiol 1997; 29: 435-441.
143. Maron BJ, Nishimura RA, Mckenna WJ, Rakowski H, Josephson ME, Kieval RS, for the M-Pathy study investigators. Assessment of permanent dual-chamber pacing as a treatment for drug refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double blind crossover study (M-Pathy). Circulation 1999; 99: 2927-2933.
144. Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB et al. ACC/AHA guidelines for implantation of cardiac pacemaker and antiarrythmia devices: A report of the Ameriacn College of Cardiology/Ameriacn Aeart Association Task Force on practice guidelines (A Committee on pacemaker implantation). J Am Coll Cardiol 1998; 31: 1175-1206.
145. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-214.
146. Kuhn H, Gietzen F, Leuner CH, Gerenkamp T. Induction of subaortic septal ischemia to reduce obstruction in hypertrophie cardiomyopathy. Studies to develop a new catheter-based concept of treatment. Eur Heart J 1997; 18: 846-851.
147. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic cardiomyopathy. Results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998; 98: 2415-2421.
148. Borggrefe M, Bolck CM, Haverkamp W, Hindricks G, Shenasa M, Breithardt G. The role of ICD in patients with dilated and hypertrophic cardiomyopathy. PACE 1992; 15: 616-626.
149. Zhu DW, Sun H, Hill R, Roberts R. The value of electrophysiology study and prophilactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 1998; 21: 299-302.
150. McIntosh CL, Maron BJ. Current operative treatment of obstructive hypertrophic cardiomyopathy. Circulation 1988; 78: 487-495.
151. Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation 1998; 98: 2505-2508.
152. Shirani J, Maron BJ, Cannon III RO, Shahin S, Roberts WC. Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation. Am J Cardiol 1993; 72: 434-440.
153. Goodwin JF. Cardiomyopathies and specific heart muscle diseases: definitions, terminology, classifications and new and old approaches. Postgrad Med J 1992;68 (Suppl 1): S3-S6.
154. Tuna IC, Danielson GK. Surgical management of pericardial diseases. Cardiol Clin 1990; 8: 683-696.
155. Huelmos A. Barba J, Martínez Caro D. Miocardiopatía restrictiva: concepto, clasificación y actitud clínica. Rev Esp Cardiol 1996; 49: 523-531.
156. Borer JS, Henry WL, Epstein SE. Echocardiographic observations in patients with systemic infiltrative disease involving the heart. Am J Cardiol 1997; 39: 184-188.
157. Appleton CP, Hatle LK, Popp RL. Demonstration of restrictive ventricular physiology by Doppler echocardiography. J Am Coll Cardiol 1988; 11: 757-768.
158. Oliver J, Domínguez F, González A, Gallego P. Miocardiopatía restrictiva. En: García Fernández MA. Principios y práctica del Doppler cardíaco. Madrid: McGraw-Hill Interamericana, 1995; 317-326.
159. a ed.). Nueva York: McGraw-Hill, 1994; 1639-1641.
160. Hatle LK, Appleton CP, Popp RL. Differentiation of constrictive pericarditis and restrictive cardiomyopathy by Doppler echocardiography. Circulation 1989; 79: 357-370.
161. Tyberg TL, Gooddyer AV, Hurst VW III, Alexander J. Langou RA. Left ventricular filling in differentiating restrictive amyloid cardiomyopathy and constrictive pericarditis. Am J Cardiol 1981; 47: 791-796.
162. Mason JW, O'Connell JB. Clinical merit of endomyocardial biopsy. Circulation 1989; 79: 971-979.
163. Masui T, Finck S, Higgins CB. Constrictive pericarditis and restrictive myocardiopathy: evaluation with MR imaging. Radiology 1992; 182: 369-373.
164. Wynne J, Braunwald E. Restrictive and infiltrative cardiomyopathies. En: Braunwald E, editor. Heart Disease. Boston: WB Saunders Co, 1997; 1426-1434.
165. Benson MD. Aging amyloid and cardiomyopathy. N Engl J Med 1997; 336: 502-504.
166. Klein Al, Hatle LK, Talicrcio CP, Oh JK, Kyle RA, Gertz MA et al. Prognostic significace of Doppler measures of diastolic function in cardiac amyloidosis: a Doppler echocardiograhic study. Circulation 1991; 83: 808-816.
167. Okayama K, Kurata C, Tawahara K, Wakabayashi Y, Chida K, Sato A. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 1995; 107: 330-334.
168. Short EM, Winkle RA, Billingham ME. Myocardial involvement in idiopathic hemochromatosis, morphological and clinical improvement following venesection. Am J Med 1981; 70: 1200-1275.
169. Navarro-López F, Llorian A, Ferrer Roca O, Betriu A, Sanz G. Restrictive cardiomyopathy in pseudoxanthoma elasticum. Chest 1980; 78: 113-115.
170. Caballero J, Calle G, Pinero C. Restricción miocárdica severa secundaria a calcificación masiva de ventrícule izquierdo. Imá-genes en cardiología. Rev Esp Cardiol 1999: 52: 53.
171. Schneider U, Jenni R, Turina J, Turina M, Hess OM. Long-term follow-up of patients with endomyocardial fibrosis: effects of surgery. Heart 1998; 79: 362-367.
172. Abelmann WH. Myocarditis. I. N Engl J Med 1966; 275: 832-834.
173. Abelmann WH. Myocarditis. II. N Engl J Med 1966; 275: 944-945.
174. Dec GW, Palacios IF, Fallon JT, Aretz HT, Mills J, Lee D et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies -clinical features, histologic correlates, and clinical outcome. N Engl J Med 1985; 312: 885-890.
175. Obrador D, Ballester M. La miocardiopatía dilatada y el problema del diagnóstico de miocarditis. Una propuesta para la superación de la polémica. En: Marín E, García Dorado D, Iñiguez Romo, Alonso Martín, Fernández Avilés, editores. Puesta al día. Insuficiencia cardíaca. Sociedad Española de Cardiología, 1993.
176. Bowles NE, Rose ML, Banner NR, Morgan-Capner P, Cunningham L. Arcnard LC et al. End-stage dilated cardiomyopathy: persistence of enterovitrus RNA in myocardium at heart transplantation and lack of immune response. Circulation 1989; 80: 1128-1136.
177. Archard LC, Bowles NE, Cunningham L, Freeke CA, Olsen EGJ, Rose ML et al. Molecular probes for detection of persisting enterovirus infection of human heart and their prognostic value. Eur Heart J 1991; 12 (Supl D): 56-59.
178. Martí V. Coll P, Ballester M, Obrador D, Carrió I. Moya C et al. Enterovirus persistence and myocardial damage detected by 111 In-monoclonal antimyosin antibodies in patients with dilated cardiomyopathy. Eur J Cardiol 1996; 17: 454-459.
179. Why HJF, Meany BT, Richardson PJ, Olsen EGJ, Bowles NE, Cunningham L et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 1994; 89: 2582-2589.
180. Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for the role of sampling error. Mayo Clin Proc 1989; 64: 1235-1245.
181. Becker AE, Heijmans CD, Essed CE. Chronic non-ischemic heart disease and endomyocardial biopsies. Worth the extra? Eur Heart J 1991; 12: 218-223.
182. Mason JW, Billingham ME, Ricci DR. Treatment of acute inflammatory myocarditis assisted by endomyocardial biopsy. Am J Cardiol 1980; 45: 1037-1044.
183. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ et al. Myocarditis. A histopathologic definition and classification. Am J Cardiov Pathol 1987: 1: 3-14.
184. O'Connell JB, Robinson JA, Henkin RE, Gunnar RM. Gallium67 citrate snanning for noninvasive detection of inflammation in pericardial diseases. Am J Cardiol 1980; 46: 879-884.
185. O'Connell IB, Henkin RE, Robinson JA, Subramaniun R, ScanIon PJ, Gunnar RM. Gallium-67 imaging in patients with dilated cardiomyopathy and biopsy-proven myocarditis. Circulation 1984; 70: 58-62.
186. Khaw BA, Gold HK, Leinbach RC, Fallon JT, Strauss W, Pohost GM et al. Early imaging of experimental myocardial infarction by intracoronary administration of 131I-labeled anticardiac myosin (Fab')2 fragments. Circulation 1978; 58: 1137-1142.
187. Khaw BA, Fallon JT, Beller GA, Haber E. Specificity of localization of myosin-specific antibody fragments in experimental myocardial infarction: histologic, histochemical, autoradiographic and scintigraphic studies. Circulation 1979; 60: 1527-1531.
188. Khaw BA, Scott J, Fallon JT, Cahill SL, Haber E, Homcy C. Myocardial injury: quantitation by cell sorting initiated with antimyosin fluorescent spheres. Science 1982; 217: 1050-1053.
189. Khaw BA, Malus JA, Melincoff G, Strauss HW, Gold HK, Haber E. Monoclonal antibody to cardiac myosin: imaging of experimental myocardial infarction. Hybridoma 1984; 3: 11-23.
190. Khaw BA, Gold HK, Yasuda T, Leinbach RC, Kankee M, Fallon JT et al. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody. Circulation 1986; 74: 501-508.
191. Yasuda T, Palacios IF, Dec W, Fallon JT, Gold HK, Leinbach RC et al. Indium 111-monoclonal antimyosin antibody imaging in the diagnosis of acute myocarditis. Circulation 1987; 76: 306-311.
192. Carrió I, Berná L, Ballester M, Estorch M, Obrador D, Cladellas M et al. Indium-111 antimyosin scintigraphy to assess miocardial damage in patients with suspected myocarditis and cardiacrejection. J Nucl Med 1988: 29: 1893-1900.
193. Dec GW, Palacios I, Yasuda T, Fallon JT, Khaw BA. Strauss HW et al. Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol 1990; 16: 97-104.
194. Narula J, Khaw BA, Dec GW Jr, Palacios IF, Fallon JT, Strauss HW et al. Recognition of acute myocarditis masquerading as acute myocardial infarction. N Engl J Med 1992; 328: 100-104.
195. Narula J, Haider N, Virmani R, DiSalvoTG, Kolodgie FD, Hajjar R et al. Apoptosis in end-stage heart failure. N Engl J Med 1996; 335: 1182-1189.
196. Obrador D, Ballester M, Carrió I, Bernà L. Pons G. High prevalence of ongoing myocyte damage in patients with chronic dilated cardiomyopathy. J Am Coll Cardiol 1989; 13: 1289-1293.
197. Obrador D, Ballester M, Carrió I, Augè JM, Moya C, Bosch I., et al. Active myocardial damage without attending inflammatory response in idiopnthic dilated cardiomyopathy. J Am Coll Cardiol 1993; 21: 1667-1671.
198. Obrador D, Ballester M, Carrió I, Moya C, Bosch I. Martí V et al. Presence, evolving changes, and prognostic implications of myocardial damage detected in idiopathic and alcoholic dilated cardiomyopathy by 111-In monoclonal antimyosin antibodies. Circulation 1994; 89: 2054-2061.
199. Ballester M, Martí V, Obrador D, Carrió I, Marrugat J. The role of 111-In-Monoclonal antimyosin antibodies in risk stratification of patients with dilated cardiomyopathy referred for heart transplantation. Transpl Proceedings 1997; 29: 589-591.
200. Maisch B, Hufnagel G, Schonian U, Hengstenberg C. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Eur Heart J 1995; 16: 173-175.